will help lead an international trial into suspected septic shock in children after receiving more than $3 million from the Federal Government.
Professor Babl, Group Leader of Emergency Research at the Murdoch Children’s Research Institute, will look at a balanced versus normal saline fluid treatment in children with sepsis.
Sepsis is a life-threatening organ failure affecting around 4 million children annually.
Professor Babl’s team will join researchers in New Zealand, the US and Canada, enrolling 8,800 children to provide the evidence necessary to change clinical practice worldwide and in turn save thousands of children’s lives.
The trial was one of three to share in $5 million to allow Australian researchers and patients to take part in international clinical trials of new, lifesaving treatments.
Australian participation in these trials will be funded under the Medical Research Future Fund’s (MRFF) International Clinical Trials Collaboration grant opportunity. The funding will support Australian research teams to establish and co-ordinate clinical trial sites and recruit patients within Australia.
Clinical trials guide the development of new drugs, devices, therapies and models of care, and allow patients to access the most recent, innovative treatments.
